Clinical Trials Logo

Gut Microbiota clinical trials

View clinical trials related to Gut Microbiota.

Filter by:

NCT ID: NCT03760133 Completed - Colonoscopy Clinical Trials

The Change of Gut Microbiota After Bowel Preparation and the Effect of Probiotics

Start date: December 1, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the relationship between the change of intestinal bacterial flora and the recovery, and the incidence of symptoms such as abdominal discomfort after colonoscopy. And the investigators will also analyze the effects of probiotics on the degree of change, recovery, and symptom development in intestinal flora.

NCT ID: NCT03746158 Completed - Gut Microbiota Clinical Trials

Interindividual Variation in Excretion of Curcumin

Start date: September 1, 2018
Phase: N/A
Study type: Interventional

The objective of this project is to elucidate the interindividual variations in excretion of curcumin and its metabolites.

NCT ID: NCT03658681 Completed - Gut Microbiota Clinical Trials

Effect of Fat Quality on Glycemic Regulation and Gut Microbiota After a Short-time Intervention in Healthy Individuals

Start date: March 13, 2018
Phase: N/A
Study type: Interventional

The overall aim is to investigate effects of saturated versus polyunsaturated fat on glycemic regulation and satiety in a postprandial study with healthy individuals. The potential effects will be related to changes in gut microbiota, the circulating levels of short chain fatty acids, inflammation and gene expression in peripheral mononuclear blood cells.

NCT ID: NCT03615651 Completed - Clinical trials for Magnetic Resonance Imaging

Probiotic Effects on the Microbe-brain-gut Interaction and Brain Activity During Stress Tasks in Healthy Subjects

Start date: January 22, 2018
Phase: N/A
Study type: Interventional

The aim of this study is to determine if and how the "Probiotic Product" affects functional brain responses in healthy subjects during an emotional- and arithmetic stress task, respectively and in terms of microbe-brain-gut interactions.

NCT ID: NCT03448094 Completed - Clinical trials for Overweight and Obesity

The Effects of Resveratrol Supplementation on Cognition, Cerebral Blood Flow, Microbiota and Systemic Inflammation.

Start date: February 6, 2018
Phase: N/A
Study type: Interventional

Previous research shows that a diet high in fat has harmful effects on gut health. This increases the chance of developing obesity-related diseases (such as type 2 diabetes) and disrupts cognition and mood. Research has suggested that gut health can be improved by taking certain supplements, including resveratrol (a polyphenol found primarily in red grape skins). Resveratrol has also been shown to improve brain blood flow and possibly brain function - however, there is limited research studying this. This study will investigate the effects of 12 weeks daily consumption of resveratrol on cognitive function, cerebral blood flow, gut microbiota and systemic inflammation in overweight and obese healthy adults.

NCT ID: NCT03308461 Completed - Constipation Clinical Trials

Fecal Microbiota Transplantation for Constipation

Start date: May 1, 2013
Phase: N/A
Study type: Interventional

Difficult defecation is a common symptom involving with patients'life quality. The stool pattern of these patients might be related to the contribution of gut microbiota. This pilot study proposed hypothesis that stool pattern could be used as a simple index to screen the potential candidates of fecal microbiota transplantation in patients with difficult defecation.

NCT ID: NCT03293693 Completed - Gut Microbiota Clinical Trials

Intake of Beta-glucan and Postprandial Regulation of Blood Glucose Metabolism in Healthy Subjects

Start date: October 2016
Phase: N/A
Study type: Interventional

The overall aim is to investigate the intake of beta-glucan in relation to glucose metabolism and satiety in a postprandial study with healthy subjects. The potential effects will be related to changes in the gut microbiota, the circulating levels of short chain fatty acids, inflammation and gene expression in peripheral mononuclear blood cells

NCT ID: NCT03232099 Completed - Atherosclerosis Clinical Trials

Red Wine Effects Upon Gut Flora and Plasma Levels of Trimethylamine-N-oxide (TMAO) - WineFlora Study

Start date: August 31, 2016
Phase: N/A
Study type: Interventional

Recent evidence indicates that Trimethylamine-N-oxide (TMAO) is a pro-atherosclerotic, phosphatidylcholine-dependent metabolite of diet and intestinal flora. Food substrates derive from carnitine and phosphatidylcholine (lecithin), present mainly in eggs, red meat, liver and pork. The intestinal flora pattern that favors the formation of TMAO is very similar to that which predisposes to insulin resistance and obesity: a high proportion between phylum Firmicutes over Bacteroidetes. The intestinal microbiota is sensitive and variable; the use of prebiotics and probiotics can change the relationship between Firmicutes/Bacteroidetes phyla. Red wine (RW), for its composition with polyphenols and possible bactericidal role, may play a role in the intestinal flora modification and could promote proliferation of beneficial bacteria. However, the influence of RW on TMAO is not known. This is the hypothesis to be tested in this trial. METHODS: This is a prospective, crossover, randomized, controlled trial with patients from Heart Institute (InCor), FMUSP and volunteers recruited through press releases. We will evaluate 42 patients, all men, with established atherosclerotic disease. Patients will be evaluated in a crossed manner: each subject receives both treatments, intervention and control (in random order), and they will be divided into 2 groups: A and B. In the first intervention stage, after 2 weeks of washout for all patients , group A receives Red Wine (RW) and group B is the control, abstemious. In the 2nd stage of intervention, after 2 weeks of washout for all patients the groups are inverted: group B receives RW; and group A will be abstemious. In the period with wine intervention, patients will receive 250 mL/day of red wine per day, for 5 days of the week, for 3 weeks. Patients will maintain their usual diet without the use of prebiotics or probiotics, or other polyphenolic derivatives. At the beginning and at the end of each stage, patients will be submitted to serum TMAO and intestinal microbiota evaluation. For the intestinal microbiota evaluation, the new generation sequencing will be used in the highly preserved portion of the 16S subunit of the rRNA gene. The determination of TMAO in plasma will be by liquid chromatography coupled to mass spectrometry. Expected results: It is expected to determine if RW acts on the intestinal flora to the point of influencing plasma TMAO concentration.

NCT ID: NCT03203044 Completed - Gut Microbiota Clinical Trials

Impact of Soylent Consumption on Human Microbiome Composition

Start date: October 10, 2016
Phase: N/A
Study type: Interventional

Soylent 2.0 is a popular meal replacement drink that is used to supplement or replace one's regular diet. Soylent is designed to fully fulfill one's nutritional needs, but its impact on the human microbiome remains unknown. This study aims to track the composition of participants' gut microbiomes before, during, and after Soylent consumption to more holistically understand its impact on microbiome health. We predict that a short term Soylent-based diet will induce observable and reversible changes to participants' gut microbiomes.

NCT ID: NCT03153059 Completed - Gut Microbiota Clinical Trials

Gut Microbiota and Stool Frequency

Start date: May 11, 2017
Phase: N/A
Study type: Observational

We hypothesized that some difference in the composition and distribution of gut microbiota in people with a large number of defecation (two or three times a day or more), people with normal defecation (one time a day or two days), and people with a small number of defecation (two times a week or less). And we investigate the association between gut microbiota and stool frequency.